Tilray Brands Inc (2HQ.BE)
| Previous close | 1.8775 |
| Open | 1.9950 |
| Bid | 1.8285 x 0 |
| Ask | 1.8390 x 0 |
| Day's range | 1.9950 - 1.9950 |
| 52-week range | 1.3930 - 3.0520 |
| Volume | |
| Avg. volume | 798 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 24 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis Rescheduling When Effective
NEW YORK and LEAMINGTON, Ontario, May 17, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY), a leading global lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell shares of its common stock (“Common Stock”) having an aggregate
ReutersCannabis stocks rally after DOJ proposal to reclassify marijuana
Cannabis stocks including Tilray, Curaleaf, and the AdvisorShares Pure US Cannabis ETF rallied on Thursday after the U.S. Department of Justice unveiled a historic proposal to ease restrictions on marijuana. Under the proposal, cannabis would be reclassified from a so-called Schedule I drug, which are considered highly additive with no medical benefits, to a Schedule III, signifying it has moderate to low potential for physical and psychological dependence. "No safety concerns were identified in the FDA's review that would indicate that medical use of marijuana poses unacceptably high safety risks," the proposal says.
Barrons.comPot Stocks Surge as Biden ‘Reschedules’ Marijuana
A change in classification is moving closer to reality. Multistate weed sellers would be the immediate beneficiaries.
